Zacks Research Upgrades ICU Medical (NASDAQ:ICUI) to “Strong-Buy”

ICU Medical (NASDAQ:ICUI) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms have also commented on ICUI. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a report on Monday, June 15th. BTIG Research assumed coverage on ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 price target for the company. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Finally, KeyCorp cut their price objective on ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $168.40.

ICU Medical Stock Performance

NASDAQ ICUI opened at $146.60 on Monday. ICU Medical has a 1 year low of $107.00 and a 1 year high of $160.29. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The firm has a market cap of $3.66 billion, a price-to-earnings ratio of 79.24, a PEG ratio of 2.07 and a beta of 0.77. The company has a fifty day moving average price of $132.26 and a 200-day moving average price of $138.42.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. During the same period last year, the firm earned $1.72 earnings per share. The firm’s revenue was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities research analysts predict that ICU Medical will post 6.5 EPS for the current fiscal year.

Insider Activity

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director directly owned 7,960 shares of the company’s stock, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Hilton Head Capital Partners LLC purchased a new stake in shares of ICU Medical during the 4th quarter valued at approximately $32,000. Covestor Ltd grew its position in shares of ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares in the last quarter. Strs Ohio increased its holdings in shares of ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the period. Rockefeller Capital Management L.P. increased its holdings in shares of ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of ICU Medical in the fourth quarter worth $120,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.